Enanta Pharmaceuticals (ENTA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ENTA Enanta Pharmaceuticals

Watchlist

8.560
-0.450-4.99%

Close Nov 26 16:00 ET

181.37MMarket Cap-1562P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Enanta Pharmaceuticals | 10-K: Annual report
SEC29minutes ago · Announcements
Oppenheimer Maintains Enanta Pharmaceuticals(ENTA.US) With Hold Rating, Cuts Target Price to $14
Moomoo News36minutes ago · Ratings
Express News | Enanta Pharmaceuticals Inc. : Oppenheimer Cuts Target Price to $14 From $16
Reuters51minutes ago
Investors Don't See Light At End Of Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Tunnel And Push Stock Down 27%
Simply Wall St05:01 ET
Enanta Pharmaceuticals Is Maintained at Outperform by Baird
Dow Jones11:19 ET · Ratings
Express News | Enanta Pharmaceuticals Shares Fall 5% After Q4 Results
ReutersNov 26 09:53 ET

Comments

Moomoo AI

Mar 5 20:53

Enanta Pharmaceuticals' P/S ratio remains low despite recent share price jump, likely due to weak revenue forecast. Market sentiment doesn't anticipate a strong share price rise soon.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Moomoo AI

Feb 12 05:23

Analysts hold a pessimistic view on Enanta Pharmaceuticals after its earnings shortfall. The consensus price target dropped significantly, suggesting lower earnings per share are a key indicator for the company's valuation. The company's long-term prospects are deemed more crucial than next year's earnings.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported And Analysts Have Been Cutting Their Estimates

Moomoo AI

Jan 18 04:42

The low P/S ratio of Enanta Pharmaceuticals may be justified by its declining revenue and poor growth outlook compared to the industry. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Moomoo AI

Dec 17, 2023 06:41

Recent insider sale at Enanta Pharmaceuticals reflects possible contentment with lower company valuation. The absence of insider buying over past year raises caution for potential investors.

Independent Director Of Enanta Pharmaceuticals Sold 73% Of Their Shares

Explore moomoo's "Insider Activity" for institutional sentiment

Analysts Notebook

Jul 6, 2022 07:10

Columns Top upgrades and downgrades on 7/6: MRK, EOG, ABT, UNP and more

Upgrades
• $A.O. Smith (AOS.US)$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum (CPE.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet (DNB.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals (ENTA.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning (GLW.US)$ : CFRA Upgrades to Strong Buy ...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

ENTA Enanta Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target